EXCLUSIVE: RenovoRx Concludes Enrollment in Phase 3 Trial of RenovoCath Drug-Delivery Device for Locally Advanced Pancreatic Cancer; Topline Data Readout Expected in 2H 2027

RenovoRx shares are trading higher after the company announced the publication of pharmacokinetic and pharmacodynamic data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers Picard Medical (AMEX:PMI) shares moved upwards by 82.7% to $9.38 during Tuesday's regular session. The market value of their outstanding shares is at $10.5 million. As per the news, the Q2 earnings report

RenovoRx Announces Publication Of Sub-Study Data From Its Ongoing Phase III TIGeR-PaC Clinical Trial In The Journal Cancer Chemotherapy And Pharmacology; Data Show Trans-Arterial Micro-Perfusion-Mediated Delivery Concentrated Chemotherapy At The Tumor Site, Extracting ~51% Of Drug Locally Before It Entered The Bloodstream, Meaningfully Lowering Systemic Exposure

RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared

8-K filing — RenovoRx, Inc. (RNXT)

Filed: 2026-08-20 AccNo: 0001493152-26-039472 Size: 202 KB Item 8.01: Other Events